Source Natural Foods & Herbal Supplements Ltd
Incorporated in 1998, Source Natural Foods and Herbal Supplements Ltd deals in ayurvedic products and green energy segment.[1]
- Market Cap ₹ 71.4 Cr.
- Current Price ₹ 111
- High / Low ₹ 170 / 96.6
- Stock P/E 20.4
- Book Value ₹ 40.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 14.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.54 | 10.93 | 15.94 | 10.84 | 12.81 | 13.59 | 24.88 | 21.53 | 19.79 | 27.30 | 44.92 | 70.38 | 79.70 | |
| 5.83 | 9.97 | 14.12 | 9.43 | 11.22 | 11.20 | 20.71 | 17.68 | 16.18 | 22.83 | 40.44 | 64.48 | 73.40 | |
| Operating Profit | 0.71 | 0.96 | 1.82 | 1.41 | 1.59 | 2.39 | 4.17 | 3.85 | 3.61 | 4.47 | 4.48 | 5.90 | 6.30 |
| OPM % | 10.86% | 8.78% | 11.42% | 13.01% | 12.41% | 17.59% | 16.76% | 17.88% | 18.24% | 16.37% | 9.97% | 8.38% | 7.90% |
| 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | 0.33 | 0.49 | 0.01 | -0.04 | 0.08 | 0.06 | 0.23 | |
| Interest | 0.01 | 0.01 | 0.07 | 0.24 | 0.20 | 0.23 | 0.10 | 0.24 | 0.27 | 0.21 | 0.62 | 0.66 | 0.76 |
| Depreciation | 0.54 | 0.49 | 0.35 | 0.35 | 0.34 | 0.34 | 0.37 | 0.42 | 0.62 | 1.04 | 0.36 | 0.38 | 0.72 |
| Profit before tax | 0.16 | 0.47 | 1.41 | 0.83 | 1.05 | 1.84 | 4.03 | 3.68 | 2.73 | 3.18 | 3.58 | 4.92 | 5.05 |
| Tax % | 0.00% | 10.64% | 0.71% | 3.61% | 2.86% | 11.41% | 16.38% | 33.97% | 22.71% | 45.28% | 18.99% | 30.89% | |
| 0.16 | 0.43 | 1.40 | 0.80 | 1.03 | 1.64 | 3.37 | 2.43 | 2.12 | 1.74 | 2.90 | 3.40 | 3.50 | |
| EPS in Rs | 0.26 | 0.67 | 2.17 | 1.24 | 1.60 | 2.55 | 5.24 | 3.78 | 3.29 | 2.70 | 4.51 | 5.28 | 5.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 62.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 23% |
| 3 Years: | 53% |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 0% |
| 3 Years: | 17% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -4% |
| 3 Years: | 7% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 13% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.10 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 | 6.44 |
| Reserves | -0.96 | -0.88 | 0.53 | 1.33 | 2.36 | 3.35 | 6.73 | 9.16 | 11.28 | 13.02 | 15.92 | 19.32 |
| 0.09 | 0.08 | 1.91 | 1.77 | 0.16 | 1.12 | 0.93 | 0.04 | 0.02 | 1.24 | 7.41 | 7.79 | |
| 0.77 | 0.98 | 2.63 | 1.56 | 1.84 | 2.23 | 3.13 | 3.69 | 3.96 | 4.18 | 6.56 | 7.38 | |
| Total Liabilities | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 36.33 | 40.93 |
| 3.66 | 3.31 | 3.53 | 3.58 | 3.57 | 3.31 | 3.88 | 5.00 | 6.56 | 5.52 | 3.93 | 4.16 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.34 | 3.31 | 7.98 | 7.52 | 7.23 | 9.83 | 13.01 | 14.33 | 15.14 | 19.36 | 32.40 | 36.77 | |
| Total Assets | 6.00 | 6.62 | 11.51 | 11.10 | 10.80 | 13.14 | 17.23 | 19.33 | 21.70 | 24.88 | 36.33 | 40.93 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.38 | 0.38 | -0.69 | 0.11 | 2.64 | -0.36 | 4.46 | -0.70 | 2.51 | 2.69 | 0.07 | -2.49 | |
| -0.40 | -0.16 | -1.95 | 0.14 | -0.31 | -0.71 | -2.09 | 0.07 | 0.06 | 0.29 | -5.33 | -2.36 | |
| 0.11 | 0.01 | 2.06 | -0.42 | -1.60 | 0.32 | 0.32 | -1.20 | -0.53 | 1.19 | 5.40 | -0.17 | |
| Net Cash Flow | 0.08 | 0.23 | -0.58 | -0.18 | 0.74 | -0.74 | 2.69 | -1.83 | 2.04 | 4.18 | 0.13 | -5.01 |
| Free Cash Flow | -0.02 | 0.24 | -1.26 | -0.29 | 2.31 | -0.44 | 3.20 | -1.90 | 2.59 | 2.69 | -0.02 | -3.10 |
| CFO/OP | 54% | 40% | -38% | 8% | 166% | -15% | 107% | -18% | 70% | 60% | 2% | -42% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12.84 | 27.72 | 100.52 | 139.06 | 94.88 | 182.37 | 87.88 | 131.22 | 136.67 | 100.41 | 99.46 | 92.68 |
| Inventory Days | 218.30 | 143.24 | 115.92 | 202.88 | 149.49 | 92.38 | 64.09 | 106.83 | 141.55 | 93.59 | 66.20 | 55.94 |
| Days Payable | 108.28 | 81.70 | 84.18 | 36.13 | 46.29 | 58.58 | 22.10 | 57.67 | 78.93 | 60.94 | 35.55 | 35.90 |
| Cash Conversion Cycle | 122.86 | 89.26 | 132.26 | 305.81 | 198.08 | 216.16 | 129.86 | 180.37 | 199.29 | 133.06 | 130.10 | 112.71 |
| Working Capital Days | 57.48 | 53.10 | 74.88 | 124.92 | 112.83 | 155.78 | 68.66 | 163.09 | 156.77 | 98.27 | 54.36 | 77.53 |
| ROCE % | 3.31% | 8.83% | 20.39% | 11.62% | 13.51% | 20.84% | 33.11% | 26.36% | 17.97% | 17.90% | 16.64% | 17.62% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Ayurvedic Medicines Share of Sale of Products % |
|
||||||||
| Number of Permanent Employees count |
|||||||||
| Ojasvita Share of Sale of Products % |
|||||||||
| Veg Capsules & Cookies Share of Sale of Products % |
|||||||||
| Power Consumption KWH |
|||||||||
Extracted by Screener AI
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Members approved K B Nambiar & Associates as statutory auditors for five years from September 30, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Closure of Trading Window
- Shareholder Meeting / Postal Ballot-Outcome of AGM
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
SNFHSL is in the business of Ayurvedic Medicines and Foods Supplements segments.
The company is expanding its portfolios in green energy vertical and is also focusing on diversification into wastewater and solid waste
management.